News
Abbott presents phase 3 study results for investigational use of HUMIRA
Abbott announced results from the Phase 3 ABILITY-2 investigational study of HUMIRA Â in patients with active peripheral spondyloarthritis (PSpA) who have not been diagnosed with psoriatic arthritis (PsA) or ankylosing spondylitis (AS). At week 12, nearly...
News
New immune therapy shows promise in kidney cancer
An antibody that helps a person's own immune system battle cancer cells shows increasing promise in reducing tumors in patients with advanced kidney cancer, according to researchers at Beth Israel Deaconess Medical Center. The results of...
News
Carfilzomib demonstrates efficacy as new frontline treatment regimen for multiple myeloma
Results from a study published online in Blood, the Journal of the American Society of Hematology (ASH), demonstrate that inclusion of carfilzomib, a novel targeted therapy for multiple myeloma, in combination with lenalidomide and low-dose dexamethasone, resulted in...
News
Trastuzumab emtansine reduced the risk of cancer worsening or death
Roche announced that the Phase III EMILIA study of trastuzumab emtansine met its co-primary endpoint, of a significant improvement in the time patients with HER2-positive metastatic breast cancer (mBC) lived without their disease getting worse. ...
News
Boehringer Ingelheim expands development capacities with new technical centre
The research driven pharmaceutical company Boehringer Ingelheim is establishing a new 50 million-plus euro pilot plant facility for the production of newly developed active pharmaceutical ingredients. The company announced this investment in its largest research...
News
Bristol-Myers Squibb announces global collaboration with leading academic institutions
Bristol-Myers Squibb Company announced the formation of the International Immuno-Oncology Network (II-ON), a global collaboration between industry and academia that aims to further the scientific understanding of immuno-oncology. Immuno-oncology focuses on the potential of...
News
Lundbeck’s Lu AE58054 meets primary endpoint
H. Lundbeck A/S today announced that Lu AE58054 has met its primary endpoint in a fixed dose, randomized, placebo-controlled clinical study in 278 patients suffering from Alzheimer's disease. The investigational compound, Lu AE58054 is...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read